Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.

The structure of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) complexed with a 19-mer/18-mer double-stranded DNA template-primer (dsDNA) and the Fab fragment of monoclonal antibody 28 (Fab28) has been refined at 2.8 A resolution. The structures of the polymerase active site and neighboring regions are described in detail and a number of novel insights into mechanisms of polymerase catalysis and drug inhibition are presented. The three catalytically essential amino acid residues (Asp110, Asp185, and Asp186) are located close to the 3' terminus of the primer strand. Observation of a hydrogen bond between the 3'-OH of the primer terminus and the side-chain of Asp185 suggests that the carboxylate of Asp185 could act as a general base in initiating the nucleophilic attack during polymerization. Nearly all of the close protein-DNA interactions involve atoms of the sugar-phosphate backbone of the nucleic acid. However, the phenoxyl side-chain of Tyr183, which is part of the conserved YMDD motif, has hydrogen-bonding interactions with nucleotide bases of the second duplex base-pair and is predicted to have at least one hydrogen bond with all Watson-Crick base-pairs at this position. Comparison of the structure of the active site region in the HIV-1 RT/dsDNA complex with all other HIV-1 RT structures suggests that template-primer binding is accompanied by significant conformational changes of the YMDD motif that may be relevant for mechanisms of both polymerization and inhibition by non-nucleoside inhibitors. Interactions of the "primer grip" (the beta12-beta13 hairpin) with the 3' terminus of the primer strand primarily involve the main-chain atoms of Met230 and Gly231 and the primer terminal phosphate. Alternative positions of the primer grip observed in different HIV-1 RT structures may be related to conformational changes that normally occur during DNA polymerization and translocation. In the vicinity of the polymerase active site, there are a number of aromatic residues that are involved in energetically favorable pi-pi interactions and may be involved in the transitions between different stages of the catalytic process. The protein structural elements primarily responsible for precise positioning of the template-primer (including the primer grip, template grip, and helices alphaH and alphaI of the p66 thumb) can be thought of functioning as a "translocation track" that guides the relative movement of nucleic acid and protein during polymerization.

[1]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .

[2]  E. Arts,et al.  Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. , 1998, Progress in nucleic acid research and molecular biology.

[3]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[4]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[5]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[6]  E. Clercq,et al.  Antiviral therapy for human immunodeficiency virus infections. , 1995 .

[7]  S D Kemp,et al.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. C. Wang.  Resolution of phase ambiguity in macromolecular crystallography. , 1985, Methods in enzymology.

[9]  R. Bambara,et al.  Mutations within the Primer Grip Region of HIV-1 Reverse Transcriptase Result in Loss of RNase H Function* , 1997, The Journal of Biological Chemistry.

[10]  E. Clercq.  In search of a selective antiviral chemotherapy. , 1997 .

[11]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[12]  M. Wainberg,et al.  The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine , 1993, Antimicrobial Agents and Chemotherapy.

[13]  S. L. Le Grice,et al.  Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. , 1994, The Journal of biological chemistry.

[14]  J. Kraut,et al.  Crystal structures of human DNA polymerase beta complexed with DNA: implications for catalytic mechanism, processivity, and fidelity. , 1996, Biochemistry.

[15]  Jianping Ding,et al.  Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer. , 1997, Biopolymers.

[16]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[17]  T. Naas,et al.  Subunit‐selective mutagenesis indicates minimal polymerase activity in heterodimer‐associated p51 HIV‐1 reverse transcriptase. , 1991, The EMBO journal.

[18]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[19]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Samuel H. Wilson,et al.  A minor groove binding track in reverse transcriptase , 1997, Nature Structural Biology.

[21]  P. Bentley,et al.  Anti-infectives: recent advances in chemistry and structure-activity relationships. The Proceedings of the 2nd International Symposium on Recent Advances in the Chemistry of Anti-infective Agents held at Churchill College, Cambridge, UK, 7-10 July 1996. , 1997 .

[22]  S. Hughes,et al.  Retroviral reverse transcription and integration: progress and problems. , 1992, Annual review of cell biology.

[23]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[24]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[25]  S. L. Le Grice,et al.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. , 1996, Biochemistry.

[26]  V. Luzzati,et al.  Traitement statistique des erreurs dans la determination des structures cristallines , 1952 .

[27]  J. Taylor,et al.  Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis , 1992, Journal of virology.

[28]  T. Darden,et al.  Reduced Frameshift Fidelity and Processivity of HIV-1 Reverse Transcriptase Mutants Containing Alanine Substitutions in Helix H of the Thumb Subdomain (*) , 1995, The Journal of Biological Chemistry.

[29]  D. Stuart,et al.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .

[30]  G. Kleywegt,et al.  Halloween ... Masks and Bones , 1994 .

[31]  R. Hamlin,et al.  [27] Multiwire area X-ray diffractometers , 1985 .

[32]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[33]  J. Hadden.  Immunotherapy of human immunodeficiency virus infection. , 1991, Trends in pharmacological sciences.

[34]  Jianping Ding,et al.  Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. , 1996, Drug design and discovery.

[35]  A. D. Clark,et al.  Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. , 1995, Methods in enzymology.

[36]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[37]  A. D. Clark,et al.  Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Clercq.  HIV resistance to reverse transcriptase inhibitors , 1994 .

[39]  Janet M. Thornton,et al.  Topological and stereochemical restrictions in β-sandwich protein structures , 1993 .

[40]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[41]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[42]  P. Argos,et al.  Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses. , 1984, Nucleic acids research.

[43]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[44]  D W Rodgers,et al.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Samuel H. Wilson,et al.  Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP. , 1994, Science.

[46]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[47]  S. Sarafianos,et al.  Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. , 1996, Biochemistry.

[48]  L. Beese,et al.  Crystal structure of a thermostable Bacillus DNA polymerase I large fragment at 2.1 A resolution. , 1997, Structure.

[49]  E. Emini,et al.  Immunological and Pharmacological Approaches to the Control of Retroviral Infections , 1997 .

[50]  E. Arnold,et al.  HIV reverse transcriptase structure-function relationships. , 1991, Biochemistry.

[51]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[52]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[53]  P Argos,et al.  An attempt to unify the structure of polymerases. , 1990, Protein engineering.

[54]  P. Boyer,et al.  A Mutation at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Interacts with Mutations at Positions 74 and 75 via the Template Primer , 1998, Antimicrobial Agents and Chemotherapy.

[55]  M. Wainberg,et al.  The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors , 1996, Antimicrobial agents and chemotherapy.

[56]  T. Teng,et al.  Mounting of crystals for macromolecular crystallography in a free-standing thin film , 1990 .

[57]  Brendan A. Larder,et al.  Site-specific mutagenesis of AIDS virus reverse transcriptase , 1987, Nature.

[58]  R. Sousa,et al.  A model for the mechanism of polymerase translocation. , 1997, Journal of molecular biology.

[59]  W A Hendrickson,et al.  Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. , 1995, Structure.

[60]  T. Eickbush,et al.  Origin and evolution of retroelements based upon their reverse transcriptase sequences. , 1990, The EMBO journal.

[61]  R F Schinazi,et al.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides , 1993, Antimicrobial Agents and Chemotherapy.

[62]  M. Bakhanashvili,et al.  Mutational studies of human immunodeficiency virus type 1 reverse transcriptase : the involvement of residues 183 and 184 in the fidelity of DNA synthesis , 1996, FEBS letters.

[63]  B. Larder.  11 Inhibitors of HIV Reverse Transcriptase as Antiviral Agents and Drug Resistance , 1993 .

[64]  J M Thornton,et al.  Pi-pi interactions: the geometry and energetics of phenylalanine-phenylalanine interactions in proteins. , 1991, Journal of molecular biology.

[65]  P Argos,et al.  A sequence motif in many polymerases. , 1988, Nucleic acids research.

[66]  D I Stuart,et al.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations , 1992, Nature.

[68]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  C. Hutchison,et al.  Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. , 1995, Nucleic acids research.

[70]  B. Larder,et al.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[71]  I Sauvaget,et al.  Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.

[72]  S. Doublié,et al.  Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 Å resolution , 1998, Nature.

[73]  M A Wainberg,et al.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine , 1992, Journal of virology.

[74]  P. Boyer,et al.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1 , 1992, Journal of virology.

[75]  M. A. McClure,et al.  Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[77]  B. Matthews.  Solvent content of protein crystals. , 1968, Journal of molecular biology.

[78]  N. Xuong,et al.  Software for a diffractometer with multiwire area detector. , 1985, Methods in enzymology.

[79]  Samuel H. Wilson,et al.  Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. , 1994, The Journal of biological chemistry.

[80]  R. Goody,et al.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P. Boyer,et al.  Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase. , 1998, Journal of molecular biology.

[82]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[83]  A. D. Clark,et al.  Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. , 1995, Biochemistry.

[84]  J. Hansen,et al.  Structure of the RNA-dependent RNA polymerase of poliovirus. , 1997, Structure.

[85]  Jianping Ding,et al.  Molecular modeling studies of HIV‐1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity , 1995, Protein science : a publication of the Protein Society.

[86]  Mike Carson,et al.  Ribbon models of macromolecules , 1987 .